Episoder
-
A mother’s immune system is altered during pregnancy so that the fetus is not rejected by her body and is allowed to grow. When this balance goes awry, the immune system may become the cause of a miscarriage or multiple miscarriages. We are talking to Dr. Jeffrey Braverman, a world leader in reproductive immunology, about the role of immune system in recurrent miscarriages. Dr. Braverman will talk about various immunity related conditions or issues that may be the cause of recurrent miscarriages, and also highlight the advances in the diagnosis and management of immune related pregnancy complications.
-
Multiple Myeloma is the second most common cancer of the blood and is largely incurable. A recent study has found that a specific gene mutation can increase the risk of developing myeloma six to nine fold. The lead author of the study and Professor of Medicine and Genetic Medicine at Weill Cornell, Dr. Steven M. Lipkin is talking to the panel on predisposition to multiple myeloma and role of precision medicine.
Expert - Dr. Steven Lipkn, Weill Cornell Medicine
Panelists - Gary Petersen, Yelak Biru, Cynthia Chmielewski, Priya Menon
RSVP here. -
Manglende episoder?
-
Over 10 million people in the US have a neurodegenerative condition. Half of these people have Alzheimer's Disease making it the most common neurodegenerative condition in the US. Among the remaining, a large population suffer from frontotemporal dementia (FTD). However, FTD and Alzheimer's are very often misdiagnosed for eachother and even the terms are used interchangeably. In reality, they are two different diseases that have varying effects on behavior. It is important to differentiate between the two so that patients and families can know what to expect and receive targeted therapies. Join us as we discuss FTD and Alzheimer's Disease, their similarities, differences, risk, diagnostic tests, progression stages, treatments and clinical trials with Dr. Murray Grossman and Dr. David Wolk from the University of Pennsylvania.
RSVP HERE! -
The treatment field of Multiple Myeloma continues to move forward as novel agents and treatment combinations expand. Whether you are standard risk patient or belong to high-risk group, treatment paradigms are getting better. We are talking to Dr. Mateos on Myeloma research and treatment modalities discussed and presented at the recently concluded American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings.
Dr. Maria Victoria Mateos is PhD Director of the Myeloma Unit University Hospital of Salamanca-IBSAL Salamanca, Spain is an Associate Professor of Hematology and Consultant Physician of the Haematology Department at the University Hospital of Salamanca, Spain.
RSVP here. -
In December 2017, the FDA approved a DNA altering medication that can reverse an inherited form of progressive blindness. Luxturna is a gene therapy which can treat a condition called Leber's Congenital Amaurosis (LCA) wherein people have inherited two faulty copies of the RPE65 gene. The therapy replaces those faulty genes with normal versions, thus erasing the mutations' harmful effects. A single injection in each eye has shown to be enough to improve lost vision. We are talking to the doctor couple, Dr. Jean Bennett of University of Pennsylvania and Dr. Albert M. Maguire of Childrens' Hospital of Philadelhia (CHOP), whose work for more than 25 years on congenital blindness led to this ground breaking FDA approval. Join us to learn about the novel therapy, details on treatment procedure and recovery.
RSVP here! -
Myeloma patients are definitely living longer. A decade ago the median survival was 3 to 4 years, while now it is in the range of 8 to 10 years. With all the new drugs and treatments that have been approved, it is possible to control the disease for a longer period of time. We are talking to Dr. Shaji Kumar to explore the treatment potential of intervening early in the disease and also touch upon how personalized therapies can help in managing myeloma efficiently.
RSVP HERE! -
Research has shown that our mental state affects the outcomes of treatment in all disease conditions, including infertility, where it may decrease the chances of conception. Couples dealing with infertility go through immense stress, often times severe depression, as the follow up and treatment of infertility itself may cause anxiety and depression.
May is Mental Health Awareness Month and we are talking to practising psychologist Dr. Alice Domar, a pioneer in the field of mind/body medicine, director of integrative care at Boston IVF and associate professor of reproductive biology at Harvard Medical School. She conducts ongoing ground-breaking research which focuses on the relationship between stress and various medical conditions, the impact of cognitive behavioral interventions, as well as the impact of lifestyle habits on mental and physical health. She has been a keynote speaker and workshop leader at conferences worldwide.
In this talk, Dr. Domar will highlight effective mind-body strategies to reduce stress, decrease physical/psychological symptoms of infertility in men and women, and develop a positive mental state which may increase the chances of conception. -
Dr. Stephan A. Grupp made history when he treated the first child with CAR T cell therapy, Emily Whitehead, who is now more than five years cancer-free. In CAR-T cell therapy, a patients own genetically altered immune cells fight cancer. We learnt about the CAR-T cell research journey and FDA approval in our discussion with Dr. Carl June of University of Pennsylvania in the first episode of our CAR-T talk series. In this episode, we are talking to Dr. Stephan A. Grupp who carried out the early pediatric trials and the global Novartis trial at CHOP leading to the FDA approval. The discussion would focus on required preparations, recovery phase and where this treatment can be availed. We will also be joined by Tom Whitehead, father of Emily Whitehead who will share his experience with the trial and progress of Emily post CAR-T cell therapy.
RSVP HERE! -
Endometriosis is a disease where cells of internal lining of the uterus starts to grow outside the uterus, mainly on organs in the pelvis, causing a maze of symptoms including not only pelvic pain, infertility, and severe menstrual cramps but many more. It affects more than 170 M women worldwide, and it affects every woman differently. Unfortunately, many women remain undiagnosed, or, are diagnosed late due to lack of understanding of the symptoms. Despite this, there is lack of research funding for diagnosis, cause, & treatments of Endometriosis, making women's options limited.
March is Endometriosis Awareness Month and the 5th Worldwide Endometriosis March took place on 24th March 2018, in 60+ countries this year, to gain attention of health policy makers and congressional representatives. In honor, we are talking to eminent endometriosis specialists, and the founders of Worldwide Endometriosis March and Endometriosis Day, Dr. Camran Nezhat and Dr. Azadeh Nezhat, all about Endometriosis and the latest advances in its diagnosis, treatment and management.
Dr Camran Nezhat has been called the Father of modern-day surgery for pioneering the field of video-assisted endoscopy. He is considered as one of the best Endometriosis specialists in California. Author of several books and recipient of numerous awards, he has been involved in research, teaching, innovating and philanthropic activities throughout life.
Dr Azadeh Nezhat is co-director of Center for Special Minimally Invasive & Robotic Surgery and performs surgery at the Stanford University Medical Center, in Palo Alto, California. Her special interest is myoma of the uterus and effects of endometriosis in young girls. -
The Broad Institute in Cambridge, Massachusetts, is one of the most sophisticated bioscience and biotechnology research centers in North America. It seeks to empower a revolution in biomedicine that will accelerate the speed at which we can conquer disease. The Metastatic Prostate Cancer Project is a new initiative being coordinated by the Broad Institute. Initially, it will allow any patient in North America with advanced or metastatic prostate cancer to contribute his personal genetic, genomic, and clinical data to the developement of the world's most comprehensive database on advanced prostate cancer permitting the entire prostate cancer research community access this database and accelerate discoveries related to the management of advanced prostate cancer. The prostate cancer panel led by Mike Scott will be talking to Dr. Eli Van Allen about the project.
Eliezer M. ("Eli") Van Allen, MD, is an Associate Member at the Broad Institute, an Assistant Professor of Medicine at Harvard Medical School, and holds clinical positions at the Dana-Farber Cancer Institute and at Brigham and Women's Hospital, in Cambridge and Boston, Massachusetts. Dr. Van Allen is an experienced researcher in the fields of computational biology and the genetics and genomics of cancer. He is also the Principal Investigator for the Metastatic Prostate Cancer Project.
Prostate Panel - Mike Scott, Paul Carpenter, Jan Manarite, Joel Nowak
RSVP here!
-
Over the last few decades, breakthrough advancements in the field of fertility has helped many infertile couples start a family successfully. Innovations like non-invasive tests that can identify genetic abnormalities and multi-gene panel tests have brought personalized medicine to reproductive health. We are talking to reproductive endocrinologist Dr. Aimee Eyvazzadeh, embryologist and founder Dr. Piraye Yurttas Beim, and neuroscientist Dr. Alan Horsager, about how recent technologies can help physicians help their patients reach their family building goals in a more focussed way.Dr.Aimee also known as the ‘Egg Whisperer; is one America’s most famous fertility doctors. She is a Harvard educated board certified OBGYN, specializing in Reproductive Endocrinology and Infertility. She is famous in the media for her Egg Freezing Parties, has been featured in magazine like People and Marie Claire, and also on number of newscasts on TV.Dr. Piraye Yurttas Beim who is on the front lines of the personalized medicine revolution, founded Celmatix in 2009 to empower women to be more proactive & informed about their fertility through better data, including genomics. She is a Fellow of the second class of the Aspen Institute Health Innovators Fellowship program, a member of the Aspen Global Leadership Network, & was named a NYC Venture Fellow by the NYCEDC, top Crain’s 40 Under 40, Top 15 founders disrupting their industries by Fortune, & a Top Female Founder by TechCrunch.Dr. Alan Horsager is the President & CEO of Episona. He is a neuroscientist and visiting Research Assistant Professor at University of Southern California, and has numerous scientific publications, issued patents and several career awards under his sleeve.
-
Lyme disease is an illness caused by the bacteria Borrelia burgdorferi, a complex microbe known as a spirochete. Lyme disease is a multi-systemic illness, if left untreated it can become a severely debilitating illness affecting the central nervous system, joints, and multiple organs, including the heart and brain. It presents in multiple-stages from: acute (early stage) to chronic (late stage or persisting) illness.
The Global Lyme Alliance is pleased to present Highlights from ILADS 18th Annual Scientific Conference, our expert panel of leading physicians will provide their insights and a summary of key data and research presented at this conference.
The patient panel includes Jackie Bailey and Jennifer Crystal. Jackie is a Nurse Practitioner at Apheresis Associates of Northern Virginia (AANV). She has been performing physical exams on donors since 2010. She has extensive experience working as a Family Nurse Practitioner. Jennifer is a writer and educator at Boston. She is working on a memoir about her journey with chronic tick-borne illness.
Expert panel:
Dr. Kenneth Liegner, Physician, Author and Patient AdvocateDr. Thomas Moorcroft, Co- founder of Origins Of Health, an Osteopathic wellness centerDr. Leo J Shea III, Clinical Associate Professor of Rehabilitation Medicine at Rusk Institute, a division of the New York University-Langone Medical CenterDr. Samuel Shor, Associate Clinical Professor, George Washington University Health Care Sciences
RSVP Here! -
The MMRF is pioneering precision medicine initiatives in multiple myeloma. This would help match patients to the most effective therapies based on their genetics and other unique factors. We are talking to Anne Quinn Young of MMRF to review myeloma research initiatives at The MMRF, specifically cover The MMRF CoMMPass Study updates, MMRF Answer Fund program, clinical trials currently recruiting and opportunities that patients can explore to share their data and participate in research efforts to accelerate precision medicine.
Featured Expert: Anne Quinn Young, VP The MMRF
Patient Panel: Gary Petersen, Jack Aiello, Cynthia Chmielewski, Matt Goldman, Priya Menon
RSVP here! -
Multiple myeloma remains incurable despite improved remissions with novel agents. Relapse eventually occurs in the form of drug-resistant disease that carries a dismal prognosis. Relapse is dependent on stem cell functions. We are talking to Dr. William Matsui of Johns Hopkins University School of Medicine to get a better understanding of the drivers of these functions and how they may lead to novel therapies for relapsed disease.
Featured Guest: William Matsui, M.D., is Professor of Oncology, Director, Multiple Myeloma Program The Sidney Kimmel Comprehensive Cancer, Johns Hopkins University School of Medicine.
Dr. Matsui's current research is focused on normal and cancer stem cell biology. His laboratory identified tumor-initiating cells in the plasma cell malignancy multiple myeloma in 2004. He has subsequently found that these cells share several cellular processes with normal stem cells that regulate self-renewal and drug resistance. Recently, his laboratory has expanded these studies and studied human pancreatic cancers and normal hematopoiesis. Dr. Matsui he has been awarded the George Santos Research Award from the Leukemia and Lymphoma Society, the Clinician Scientist Award from Johns Hopkins University, and teaching awards from the Departments of Oncology and Medicine.
Panel: Gary Petersen, Jack Aiello, Cynthia Chmielewski, Yelak Biru, Priya Menon
RSVP HERE!
-
Surrogacy is a method of assisted reproduction for people who are either unable to conceive due to medical complications, or any other reason. It is an agreement where a woman agrees to carry a pregnancy for a couple or a person, who will become the baby's parent after birth. Surrogacy has been a controversial issue around the world and involves a lot of complicated contracts that intended parents as well as surrogates need to abide by. We are discussing the medical and legal aspects of surrogacy with reproductive endocrinologist Dr. Aimee D. Eyvazzadeh, reproductive/fertility lawyer Greggory M Field, and Emily M Field who became a mother through surrogacy.Dr.Aimee also known as the ‘Egg Whisperer; is one America’s most famous fertility doctors. She is a Harvard educated board certified OBGYN, specializing in Reproductive Endocrinology and Infertility. But it’s her Egg Freezing Parties that made her a media darling. She has been featured in magazine like People and Marie Claire, and has also been featured on the Today Show, Good Morning America, CBS Morning, and Fox Network, along with a number of other newscasts. Her goal it to teach everyone about fertility awareness and how to #GetAheadOfInfertility.Mr. Greggory M Field is an Attorney and Partner with Field Fertility, Goldfarb, Zeidner & Field Attorneys at Law. A “Rising Star” awardee and a member of several prestigious societies, as a Third Party Reproductive Lawyer, Mr. Field represents surrogates, egg donors, intended parents, and embryo donors.Emily Dubin Field is a mom thanks to IVF and surrogacy - after a long and emotional fertility journey, which she is very open about. She has her MBA in nonprofit management, and is also a member of the Society of Ethics of Egg Donation and Surrogacy.
-
FDA approval of the breakthrough CAR-T cell therapy for cancer brings the first approved gene therapy treatment to the United States. It reprograms the body's own immune system to recognize and kill cancer cells. The therapy initially called CAR-T cell immunotherapy and now named Kymriah by Novartis, is approved to treat children and young adults with a recurrent form of the the blood cancer called acute lymphoblastic leukemia (ALL). Dr. Carl June of University of Pennsylvania, is one of the pioneers of CAR-T cell research and leads the team responsible for the historic FDA approval. We are discussing Dr. June's CAR-T cell journey to understand nuances of the new therapy. The discussion will also bring to focus the opportunity that these engineered immune cells present to cancer treatment and possible use in treatment of other cancers.
RSVP HERE! -
In 2017 stem cell transplants remain a key option for treatment of eligible multiple myeloma patients, and in majority of patients it is done as a part of frontline therapy. Research shows that stem cell transplants significantly increases the amount of time, for which a patient has their disease under control. How safe are transplants? Who is eligible to get one? What are the side effects and how can patients tackle them? The myeloma panel is talking to Dr. Rafael Fonseca for answers to these and more on the latest developments in stem cell transplant technology in multiple myeloma treatment.
Dr. Fonseca is currently deputy director, Mayo Clinic Cancer Center, Getz Family Professor of Cancer and professor of medicine, Mayo Clinic College of Medicine, as well as site director, hematological malignancies, Mayo Clinic, Scottsdale, Arizona. Dr. Fonseca is a fellow of the International Society of Hematology and is board certified in internal medicine, medical oncology, and hematology. In addition, he holds professional memberships in the American Association of Cancer Research, American Society of Hematology, American Society of Clinical Oncology, and the Mexican Society of Internal Medicine, among others. Dr. Fonseca is a reviewer for numerous journals including American Journal of Hematology, American Journal of Medicine, Blood, British Journal of Haematology, Circulation, Hematologica, International Journal of Cancer, Journal of Clinical Oncology, Leukemia, New England Journal of Medicine, and is on the editorial board of Molecular Cancer Therapeutics, and Leukemia. He has written more than 100 peer-reviewed articles, book chapters, and abstracts. Dr. Fonseca has developed an expertise in the management of plasma cell disorders. His clinical practice is primarily composed of patients with multiple myeloma, primary amyloidosis, and monoclonal gammopathy.
-
Most multiple myeloma patients, even those in complete response, may show signs of relapse at some point of time. So, testing and quantifying Minimal Residual Disease (MRD) has become essential to obtain better prognostic correlations. Researchers believe that MRD testing could help them compare myeloma therapy strategies, evaluate new treatments faster, and guide treatment decisions. Our myeloma panelists are talking to Dr. Ola Landgren, a lead researcher in the field, on what MRD testing could mean to your treatment, and about how MRD testing could become a new and earlier end-point in myeloma treatment.
-
Multiparametric MRI (mpMRI) is being considered as a game-changer in prostate cancer treatment and management. Our prostate cancer panel of Mike Scott, Tony Crispino, Allen Edel and Joel Nowak is talking to Dr. Antonio Carlos Westphalen about the current roles of MRI and mpMRI in diagnosis and management of prostate cancer. The panel will touch upon current roles of older forms of bone scanning and CT as well as discuss the evolving roles of newer imaging techniques in the diagnosis and management of high risk and metastatic prostate cancer. Issues on access to high quality imaging and role of the expert uro-radiologist in diagnosis and management of prostate cancer are some of the other aspects that will be covered in this discussion.
RSVP HERE! -
Male factor infertility accounts for 50% of total cases of troubled conception. Unfortunatley male infertility is not as promptly reported as female infertility which is tracked by Society for Assisted Reproductive Technology database. One key reason for under-reporting of male infertility is lesser availability of means of tracking it. When it comes to fertility testing, where women have quite a few over the counter products, men have very limited options. Curetalks male fertility advocates and panelists Kristen Darcy, Sara Naab, and Jonathan Boldt are talking to Dr. Jamin Brahmbhatt to learn about new options available for men and also discuss novel advancements in techniques to check male fertility status.
- Vis mere
